Susan Graf
Président chez FINCH THERAPEUTICS GROUP, INC.
Fortune : 374 $ au 30/04/2024
Profil
Susan E.
Graf is currently the Independent Chairman at Finch Therapeutics Group, Inc. since 2022, the Director at Kaleo, Inc. since 2021, and the Independent Director at CG Oncology, Inc. since 2023.
Previously, she served as the Chief Executive Officer at Akamara Therapeutics, Inc. from 2019 to 2021.
She also held positions as a Director at Vitrisa Therapeutics, Inc., Vice President-Corporate Development & Strategy at NPS Pharmaceuticals, Inc. from 2013 to 2015, and Chief Financial & Business Officer at Epizyme, Inc. from 2016 to 2018.
Ms. Graf obtained an undergraduate degree from Purdue University and an MBA from The Leonard N Stern School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 09/06/2023 | 167 ( 0,01% ) | 374 $ | 30/04/2024 |
Postes actifs de Susan Graf
| Sociétés | Poste | Début |
|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Président | 25/04/2022 |
| CG ONCOLOGY, INC. | Directeur/Membre du Conseil | 20/11/2023 |
Kaleo, Inc.
 Kaleo, Inc. Pharmaceuticals: MajorHealth Technology Kaleo, Inc. develops drug/device combination products. Its products empower patients to gain freedom from their medical condition. The firm's capabilities include drug development, device development, regulatory and clinical, manufacturing, commercialization and data generation. The company was founded by Eric S. Edwards and Evan T. Edwards in 2005 and is headquartered in Richmond, VA. | Directeur/Membre du Conseil | 01/12/2021 |
Anciens postes connus de Susan Graf
| Sociétés | Poste | Fin |
|---|---|---|
Akamara Therapeutics, Inc.
 Akamara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akamara Therapeutics, Inc. provides medical services. The company is headquartered in Philadelphia, PA. | Directeur Général | 01/05/2021 |
| EPIZYME, INC. | Directeur Financier/CFO | 30/09/2018 |
| NPS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/03/2015 |
Vitrisa Therapeutics, Inc.
 Vitrisa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vitrisa Therapeutics, Inc. manufactures pharmaceutical products. The company was founded by Carl Erickson and is headquartered in Larkspur, CA. | Directeur/Membre du Conseil | - |
Formation de Susan Graf
| Purdue University | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CG ONCOLOGY, INC. | Health Technology |
| FINCH THERAPEUTICS GROUP, INC. | Health Services |
| Entreprise privées | 5 |
|---|---|
NPS Pharmaceuticals, Inc.
 NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ. | Health Technology |
Kaleo, Inc.
Kaleo, Inc. Pharmaceuticals: MajorHealth Technology Kaleo, Inc. develops drug/device combination products. Its products empower patients to gain freedom from their medical condition. The firm's capabilities include drug development, device development, regulatory and clinical, manufacturing, commercialization and data generation. The company was founded by Eric S. Edwards and Evan T. Edwards in 2005 and is headquartered in Richmond, VA. | Health Technology |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Vitrisa Therapeutics, Inc.
Vitrisa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vitrisa Therapeutics, Inc. manufactures pharmaceutical products. The company was founded by Carl Erickson and is headquartered in Larkspur, CA. | Health Technology |
Akamara Therapeutics, Inc.
Akamara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akamara Therapeutics, Inc. provides medical services. The company is headquartered in Philadelphia, PA. | Health Technology |